May 20th 2025
Innoviva Specialty Therapeutics’ antibiotic is the first and only FDA-approved cephalosporin indicated to treat Staphylococcus aureus bacteremia, including right-sided endocarditis, caused by the methicillin-resistant Staphylococcus aureus.
When Should We De-Escalate Empiric Antimicrobials?
May 6th 2025De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.
Read More
Addressing Gram-Negative Infections With Further Insights From Cefiderocol's PROVE Study
May 5th 2025Sean Nguyen PharmD, BCIDP, medical director Shionogi, delves into the European cohort portion of the study and offers further information from the trial and some of its bigger clinical ramifications.
Read More
Prompts in Computerized Order Entry Improve Antimicrobial Treatment for Skin, Soft Tissue Infections
May 4th 2025The INSPIRE 3 trial demonstrates that computerized order entry recommendation prompts can reduce empiric use of broad-spectrum antibiotics in favor of targeted treatment for skin and soft tissue infections.
Read More
Rifaquizinone: A Novel Rifamycin-Quinolone Hybrid Antibiotic
April 28th 2025Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.
Read More
The Impact of the Pandemic on Antimicrobial Resistance
April 21st 2025A Centers for Disease Control and Prevention study looked at the COVID-19 pandemic's effect on hospital-onset infections. Study lead author Hannah Wolford offers insights on it, including what patient populations were most affected, and the significance of infection prevention strategies.
Read More
CDC: Hospitals Experiencing Inconsistent Declines in Resistant Infections
March 20th 2025A long-term study conducted by the Centers for Disease Control and Prevention (CDC) shows early success in the reduction of such infections followed by an increase again during the early pandemic years. Additionally, certain pathogens overall saw an increase, whereas other infections were stable or saw decreases.
Read More
Study Insights on Aztreonam and Avibactam for Complicated Intra-Abdominal Infections
February 25th 2025Todd Riccobene, PhD, senior scientific director, Anti-Infectives and Infectious Diseases, US Medical Affairs + Health Impact at AbbVie provides more information on the newly approved antibiotic combination for these infections.
Read More